Skip Navigation LinksHome > January 2012 - Volume 112 - Issue 1 > Ondansetron (Zofran) Warning Strengthened
AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000410355.34028.8a
Drug Watch

Ondansetron (Zofran) Warning Strengthened

Aschenbrenner, Diane S. MS, RN

Collapse Box

Abstract

* The antiemetic ondansetron (Zofran) has undergone a label revision to emphasize the risk of cardiac arrhythmias such as QT-interval prolongation and torsade de pointes.

* Patients with congenital long QT syndrome shouldn't receive ondansetron.

* Cardiac monitoring should be conducted in patients taking ondansetron who have electrolyte imbalances, congestive heart failure, bradyarrythmias, or a history of taking other drugs that prolong the QT interval.

© 2012 Lippincott Williams & Wilkins, Inc.

Login